Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure

Cardiovascular Drugs and Therapy

Volumn 12, Issue 3, 1998, Pages 291-299

  Anand, Inder ^a   Chandrashekhan, Yam ^b   De Giuli, Federica ^c   Pasini, Evasio ^c   Mazzoletti, Anna ^d   Confortini, Roberta ^d   Ferrari, Roberto ^d  

^a VA MEDICAL CENTER   (United States)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^c Fondazione Clinica del Lavoro   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Congestive heart failure; Propionyl L carnitine; Treatment of heart failure

Indexed keywords

PROPIONYLCARNITINE;

ADULT; ARTICLE; CARNITINE DEFICIENCY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFECT; EXERCISE; FEMALE; HEART LEFT VENTRICLE VOLUME; HEART RATE; HEART VENTRICLE FUNCTION; HEMODYNAMICS; HORMONE DETERMINATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG WEDGE PRESSURE; MALE; METABOLISM; NORADRENALIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; OXYGEN CONSUMPTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PULMONARY ARTERY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; CARDIOTONIC AGENTS; CARNITINE; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HORMONES; HUMANS; MALE; MIDDLE AGED; NEUROSECRETORY SYSTEMS; OXYGEN CONSUMPTION; SINGLE-BLIND METHOD; TIME FACTORS; VENTRICULAR FUNCTION;

EID: 0031717287     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007721917561     Document Type: Article

References (52)

1. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990; 82:1730-1736.
2. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic heart failure. N Engl J Med 1991;325: 303-310.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
4. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 1992;327:669-677.
5. Ziesche S, Cobb FR, Cohn JN, Johnson G, Tristani F. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993;87(Suppl.): VI56-VI64.
6. Poole Wilson PA, Ferrari R. Role of skeletal muscle in the syndrome of chronic heart failure. J Mol Cell Cardiol 1996;28:2275-2285.
7. Siliprandi N, Di Lisa F, Pieralisi G, Ripari P, Maccari F, Menabo' R, Giamberardino MA, Vecchiet L. Metabolic changes induced by maximal exercise in human subjects following L-carnitine administration. Biochem Biophys Acta 1990;1034:17-21.
8. Bremer J. Carnitine-metabolism and functions. Physiol Rev 1983;63:1420-1480.
9. Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: A multicenter, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol 1985;23:569-572.
10. Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: A double-blind, cross-over study. Circulation 1988;77:767-783.
11. Tripp ME, Katcher ML, Peters HA, et al. Systemic carnitine deficiency presenting as familiar endocardial fibroelastosis. A treatable cardiomyopathy. N Engl J Med 1980;305: 385-390.
12. Waber LJ, Valle D, Neill C, Di Mauro S, Shug A. Carnitine deficiency presenting as familial cardiomyopathy: A treatable defect in carnitine transport. J Pediatr 1982;101: 700-705.
13. Suzuki Y, Masumuro Y, Kobayashi A, Yamazaki L, Harada Y, Osawa M. Myocardial carnitine deficiency in congestive heart failure. Lancet 1982;1:116.
14. Regitz V, Shug AL, Fleck E. Defective myocardial metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart disease. Am J Cardiol 1990;65:755-760.
15. Regitz V, Shug AL, Schuler S, Yankah AC, Hetze R. Herzin-sufficienz bei dilatativer kardiomyopathie und koronarer herzerkrankung - beitrag biochemischer parameter zur beurteilung der prognose. Dtsch Med Wochenscher 1988;113: 781-786.
16. Regitz V, Muller M, Schuler S, Yankah CA, Heyzer R, Shug AL, Fleck E. Carnitinstoffwechsel-veranduregen in endetadium der dilatativen kardiomyopathie und der ischamischen herzmuskeler-krankung. Kardiologie 1987;76:1-8.
17. Figueiredo Ramos ACM, Elian PRP, Barrucand L, Da Silva JAF. The protective effect of carnitine in human diptheric myocarditis. Pediatr Res 1984;18:815-819.
18. De Leonardis V, Neri B, Baculli S, Cinelli P. Reduction cardiac toxicity of anthracyclines by L-carnitine: Preliminary overview of clinical data. Int J Clin Pharmacol Res 1985; 5:137-142.
19. Mancini M, Rango FC, Lincetti M, Sorrentino GP, Nolfe G. Controlled study on the therapeutic efficacy on propionyl-L-carnitine in patients with congestive heart failure. Arzneim Htelforschung 1992;42(II):1101-1104.
20. Caponnetto S, Canale C, Masperone MA, Terracchini V, Valentini G, Brunelli C. Efficacy of L-propionyl-carnitine treatment in patients with left ventricular dysfunction. Eur Heart J 1994;15:1267-1273.
21. Paulson DJ, Traxler J, Shmidt M, Noonan J, Shug AL. Protection of the ischaemic myocardium by L-propionyl-carnitine: Effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport on fatty acid oxidation. Cardiovasc Res 1986;20:536-541.
22. Siliprandi N, Di Lisa F, Pivetta A, Miotto G. Siliprandi D. Transport and function of L-carnitine and L-propionyl-carnitine relevance to some cardiomyopathies and cardiac ischaemia. Z Kardiol 1987;76:34-40.
23. Tassani V, Cattapan L, Magnanimi L, Peschechera A. Anaplerotic effect of propionyl-L-carnitine in rat heart mitochondria. Biochem Biophys Res Comm 1994;199:949-953.
24. Di Lisa F, Menabo R, Siliprandi N. L-propionyl-carnitine protection of mitochondria in ischemic rat hearts. Mol Cell Biochem 1989;88:169-173.
25. Ferrari R, Di Lisa F, de Jong JW, et al. Prolonged propionyl-L-carnitine pretreatment of rabbit: Biochemical hemodynamic and electrophysiological effects on myocardium. J Mol Cell Cardiol 1992;24:219-232.
26. Yang XP, Samaja M, English E, et al. Hemodynamic and metabolic activities of propionyl-L-carnitine in rats with pressure-overload cardiac hypertrophy. J Cardiovasc Pharmacol 1992;20:88-98.
27. Micheletti R, Giacalone G, Reggiani C, Canepari M, Bianchi G. Effect of propionyl-L-carnitine treatment on mechanical properties of papillary muscles from pressure overloaded muscle. J Mol Cell Cardiol 1992;24:41-49.
28. Micheletti R, Di Paola ED, Schiavone A, et al. Propionyl-L-carnitine limits chronic ventricular dilation after myocardial infarction in rats. Am J Physiol 1993;264:H111-H117.
29. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin: Studies of body water and sodium, renal function, hemodynamic indices, and plasma hormones in untreated congestive cardiac failure. Circulation 1989;80:299-305.
30. Ferrari R, Ceconi C, Signorini C, Anand IS, Harris P, Albertini A. Sample treatment for long distance air transport of human plasma hormone assay. Clin Chem 1989;35: 331-332.
31. Ferrari R, Ceconi C, Rodella A, Harris P, Visioli O. Hormonal response in untreated myocardial infarction. Cardioscience 1990;1:55-61.
32. Poiesi C, Rodella A, Mantero G, Cannella G, Ferrari R, Albertini A. Improved radioimmunoassay of atrial natriuretic peptide in plasma. Clin Chem 1989;35:1431-1434.
33. Ferrari R, Pasini E, Condorelli E, Cargnoni A, De Giuli F, Visioli O. Effect of propionyl-L-carnitine on mechanical function of isolated and perfused hearts. Cardiovasc Drugs Ther 1991;5:109-115.
34. Cevese A, Schena F, Cerutti G. Short term hemodynamic effects of intravenous propionyl-L-carnitine in anesthethized dogs. Cardiovasc Drugs Ther 1991;5:137-148.
35. Chiddo A, Cagione A, Musci S, Troito G, Crimaldi N, Locuratolo N, Rizzon P. Haemodynamic studies in patients with coronary artery disease and normal left ventricular function. Cardiovasc Drugs Ther 1991;5:107-112.
36. Bartels L. Effects of L-propionyl-carnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol 1994;74:125-130.
37. Chiddo A, Mussi F, Bordone A, Troito G, Locuratolo N, Caglione A, Rizzon P. Effetti emodinamici e sul circolo coronarico della propionyl-L-carnitina. Cardiologia 1989;34: 111-117.
38. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation 1988;77:721-730.
39. Anand IS, Kalra GS, Harris P, Poole Wilson PA, Panzali A, de Giuli F, Ferrari R., Diuretics as initial and sole treatment in chronic cardiac failure. Cardioscience 1991;2:273-278.
40. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
41. Packer M. The neurohumoral hypothesis: A theory to explain the mechanism of disease progression in heart failure [editorial]. J Am Coll Cardiol 1992;20:248-254.
42. Wilson JR, Mancini DM. Factors contributing to the exercise limitation of heart failure. J Am Coll Card 1993;4: 93A-98A.
43. Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol 1981;47: 33-39.
44. Wilson JR, Martin JL, Schwartz D, Ferra N. Exercise intolerance in patients with congestive heart failure: Role of impaired skeletal muscles nutritive flow. Circulation 1984; 69:1079-1087.
45. Lipkin DP, Canepa-Anson R, Stephens MR, Poole-Wilson PA. Factors determining symptoms in heart failure: Comparison of fast and slow exercise tests. Br Heart J 1986;55: 439-445.
46. Drexler H, Banhardt M, Meinertz T, Wollschalager H, Lehmann M, Just H. Contrasting peripheral short term and long term efforts of converting enzyme inhibition in patients with congestive heart failure. Circulation 1989;79:491-502.
47. Wilson JR, Mancini DM. The mechanism of exertional fatigue in heart failure. Cardioscience 1990;1:13-19.
48. Wilson JR, Fink L, Maris J, Ferraro N, Power-Vanwart J, Eleff S, Change B. Evaluation of skeletal muscle energy metabolism in patients with heart failure using gated phosphorous-31 nuclear magnetic resonance. Circulation 1985; 71:57-62.
49. Mancini DM, Ferraro N, Tuchler M, Change B, Wilson JR. Detection of abnormal calf muscle metabolism in patients with heart failure using phosphorous-31 nuclear magnetic resonance. Am J Cardiol 1988;62:1234-1240.
50. Drexler H, Riede U, Schafer HE, Just H. Reduced oxidative capacity of skeletal muscles in patients with severe heart failure. Circulation 1987;76(Suppl. IV):178.
51. Ferrari R, Cargnoni A, de Giuli F, Pasini E, Anand IS, Visioli O. Propionyl-L-carnitine improves skeletal muscle metabolism and exercise capacity of patients with congestive heart failure (abst). Circulation 1993;88:I414.
52. Siliprandi N. L-Carnitine. Lancet 1990;335:1215.